PETAH TIKVA (dpa-AFX) - Par Pharmaceutical Companies, Inc. (PRX) said it acquired rights to three products from Teva Pharmaceuticals (TEVA) in connection with Teva's acquisition of Cephalon.
Under terms of the agreement, Par will own the ANDAs of fentanyl citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix, as well as the U.S. rights to market modafinil tablets, the generic version of Provigil.
Par is currently shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva.
Copyright RTT News/dpa-AFX
© 2011 AFX News
